Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 6.65
NAS:EDIT's Cash-to-Debt is ranked lower than
59% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. NAS:EDIT: 6.65 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:EDIT' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.11  Med: 9.6 Max: No Debt
Current: 6.65
Equity-to-Asset 0.50
NAS:EDIT's Equity-to-Asset is ranked lower than
69% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:EDIT: 0.50 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:EDIT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.56  Med: 0.65 Max: 0.81
Current: 0.5
-0.56
0.81
Debt-to-Equity 0.26
NAS:EDIT's Debt-to-Equity is ranked higher than
51% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:EDIT: 0.26 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:EDIT' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.03  Med: 0.15 Max: 0.34
Current: 0.26
-0.03
0.34
Debt-to-EBITDA -0.43
NAS:EDIT's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. NAS:EDIT: -0.43 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:EDIT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.47  Med: -0.25 Max: -0.03
Current: -0.43
-0.47
-0.03
Altman Z-Score: 2.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -2072.90
NAS:EDIT's Operating Margin % is ranked lower than
83% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. NAS:EDIT: -2072.90 )
Ranked among companies with meaningful Operating Margin % only.
NAS:EDIT' s Operating Margin % Range Over the Past 10 Years
Min: -2167.71  Med: -1886.67 Max: -1605.62
Current: -2072.9
-2167.71
-1605.62
Net Margin % -2091.36
NAS:EDIT's Net Margin % is ranked lower than
84% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. NAS:EDIT: -2091.36 )
Ranked among companies with meaningful Net Margin % only.
NAS:EDIT' s Net Margin % Range Over the Past 10 Years
Min: -4475.14  Med: -3040.34 Max: -1605.53
Current: -2091.36
-4475.14
-1605.53
ROE % -66.74
NAS:EDIT's ROE % is ranked lower than
64% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. NAS:EDIT: -66.74 )
Ranked among companies with meaningful ROE % only.
NAS:EDIT' s ROE % Range Over the Past 10 Years
Min: -377.64  Med: -377.64 Max: -66.74
Current: -66.74
-377.64
-66.74
ROA % -39.71
NAS:EDIT's ROA % is ranked lower than
56% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:EDIT: -39.71 )
Ranked among companies with meaningful ROA % only.
NAS:EDIT' s ROA % Range Over the Past 10 Years
Min: -186.58  Med: -90.25 Max: -39.71
Current: -39.71
-186.58
-39.71
ROC (Joel Greenblatt) % -319.05
NAS:EDIT's ROC (Joel Greenblatt) % is ranked higher than
53% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. NAS:EDIT: -319.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:EDIT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2186.08  Med: -2178.41 Max: -319.05
Current: -319.05
-2186.08
-319.05
GuruFocus has detected 1 Warning Sign with Editas Medicine Inc NAS:EDIT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:EDIT's 30-Y Financials

Financials (Next Earnings Date: 2017-11-07)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

EDIT Guru Trades in Q3 2016

Jim Simons 128,400 sh (+475.68%)
Andreas Halvorsen 1,709,401 sh (unchged)
» More
Q4 2016

EDIT Guru Trades in Q4 2016

Andreas Halvorsen 1,709,401 sh (unchged)
Jim Simons Sold Out
» More
Q1 2017

EDIT Guru Trades in Q1 2017

Paul Tudor Jones 26,185 sh (New)
John Paulson 50,000 sh (New)
Leon Cooperman 50,000 sh (New)
Andreas Halvorsen 1,709,401 sh (unchged)
» More
Q2 2017

EDIT Guru Trades in Q2 2017

Paul Tudor Jones 31,894 sh (+21.80%)
John Paulson 50,000 sh (unchged)
Andreas Halvorsen 1,709,401 sh (unchged)
Leon Cooperman Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:EDIT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Leon Cooperman 2017-06-30 Sold Out 0.04%$13.66 - $22.32 $ 24.0133%0
Leon Cooperman 2017-03-31 New Buy0.04%$17.04 - $27.27 $ 24.0116%50,000
John Paulson 2017-03-31 New Buy0.01%$17.04 - $27.27 $ 24.0116%50,000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:RETA, SZSE:300497, NAS:IMGN, NAS:BOLD, XKRX:003000, NAS:VNDA, NAS:KERX, XSWX:HBMNE, NAS:ADRO, NAS:TGTX, NAS:BYSI, NAS:ENTA, NAS:ANIK, XKRX:102940, XKRX:095700, NAS:RVNC, NAS:NTLA, XSWX:BSLN, TSE:2931, BOM:540701 » details
Traded in other countries:8EM.Germany,
Headquarter Location:USA
Editas Medicine Inc is a genome editing company which is engaged in treating patients with genetically defined diseases by correcting disease-causing genes.

Editas Medicine Inc is a US-based genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company operates its business in a single segment of Developing and commercializing genome editing technology.

Ratios

vs
industry
vs
history
PB Ratio 5.36
EDIT's PB Ratio is ranked lower than
61% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. EDIT: 5.36 )
Ranked among companies with meaningful PB Ratio only.
EDIT' s PB Ratio Range Over the Past 10 Years
Min: 2.74  Med: 4.4 Max: 7.35
Current: 5.36
2.74
7.35
PS Ratio 163.37
EDIT's PS Ratio is ranked lower than
89% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. EDIT: 163.37 )
Ranked among companies with meaningful PS Ratio only.
EDIT' s PS Ratio Range Over the Past 10 Years
Min: 57.28  Med: 110.75 Max: 170.14
Current: 163.37
57.28
170.14
Price-to-Free-Cash-Flow 67.99
EDIT's Price-to-Free-Cash-Flow is ranked lower than
79% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. EDIT: 67.99 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
EDIT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 22.64  Med: 32.53 Max: 70.85
Current: 67.99
22.64
70.85
Price-to-Operating-Cash-Flow 57.51
EDIT's Price-to-Operating-Cash-Flow is ranked lower than
79% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 25.45 vs. EDIT: 57.51 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
EDIT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 20.08  Med: 28.48 Max: 59.83
Current: 57.51
20.08
59.83
EV-to-EBIT -6.21
EDIT's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. EDIT: -6.21 )
Ranked among companies with meaningful EV-to-EBIT only.
EDIT' s EV-to-EBIT Range Over the Past 10 Years
Min: -17.5  Med: -5.3 Max: -2.4
Current: -6.21
-17.5
-2.4
EV-to-EBITDA -6.29
EDIT's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. EDIT: -6.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
EDIT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.7  Med: -5.4 Max: -2.5
Current: -6.29
-17.7
-2.5
EV-to-Revenue 128.82
EDIT's EV-to-Revenue is ranked lower than
82% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. EDIT: 128.82 )
Ranked among companies with meaningful EV-to-Revenue only.
EDIT' s EV-to-Revenue Range Over the Past 10 Years
Min: 45.1  Med: 85.1 Max: 280.9
Current: 128.82
45.1
280.9
Current Ratio 6.73
EDIT's Current Ratio is ranked higher than
68% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. EDIT: 6.73 )
Ranked among companies with meaningful Current Ratio only.
EDIT' s Current Ratio Range Over the Past 10 Years
Min: 1.74  Med: 14.79 Max: 28.66
Current: 6.73
1.74
28.66
Quick Ratio 6.73
EDIT's Quick Ratio is ranked higher than
69% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. EDIT: 6.73 )
Ranked among companies with meaningful Quick Ratio only.
EDIT' s Quick Ratio Range Over the Past 10 Years
Min: 1.74  Med: 14.79 Max: 28.66
Current: 6.73
1.74
28.66
Days Sales Outstanding 53.08
EDIT's Days Sales Outstanding is ranked higher than
61% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. EDIT: 53.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
EDIT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.31  Med: 116.82 Max: 228.32
Current: 53.08
5.31
228.32

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 6.96
EDIT's Price-to-Net-Cash is ranked higher than
52% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. EDIT: 6.96 )
Ranked among companies with meaningful Price-to-Net-Cash only.
EDIT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.75  Med: 5.57 Max: 7.07
Current: 6.96
3.75
7.07
Price-to-Net-Current-Asset-Value 6.82
EDIT's Price-to-Net-Current-Asset-Value is ranked higher than
52% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. EDIT: 6.82 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
EDIT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.65  Med: 5.47 Max: 6.93
Current: 6.82
3.65
6.93
Price-to-Tangible-Book 5.31
EDIT's Price-to-Tangible-Book is ranked lower than
52% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. EDIT: 5.31 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EDIT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.82  Med: 4.36 Max: 6.28
Current: 5.31
2.82
6.28
Price-to-Median-PS-Value 1.47
EDIT's Price-to-Median-PS-Value is ranked lower than
74% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. EDIT: 1.47 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EDIT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.68  Med: 0.93 Max: 1.5
Current: 1.47
0.68
1.5
Earnings Yield (Greenblatt) % -16.10
EDIT's Earnings Yield (Greenblatt) % is ranked lower than
66% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. EDIT: -16.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EDIT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -41.1  Med: -18.9 Max: -5.7
Current: -16.1
-41.1
-5.7

More Statistics

Revenue (TTM) (Mil) $5.64
EPS (TTM) $ -3.25
Short Percentage of Float20.99%
52-Week Range $12.43 - 29.20
Shares Outstanding (Mil)41.74

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 10 16 58 70
EPS ($) -3.57 -4.38 -4.93 -5.84
EPS without NRI ($) -3.57 -4.38 -4.93 -5.84
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}